Blood Pressure Medications: Lisinopril, Losartan, Amlodipine, Beta-Blockers Guide

Why antihypertensive drug choice matters

Hypertension affects approximately 1.28 billion adults worldwide ↗ and is the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease. Despite over 10 drug classes available, fewer than half of treated patients achieve target blood pressure — often because of suboptimal drug selection, dose under-titration, or poor adherence due to side effects.

Understanding the pharmacology of each drug class — mechanism, renal/hepatic handling, drug interactions, and population-specific effects — is essential for selecting the right regimen. This guide covers all major antihypertensive classes with attention to the pharmacokinetic and pharmacodynamic properties most relevant to clinical practice.

Antihypertensive drug classes at a glance

Class	Examples	Mechanism	Key indications	Main cautions
ACE inhibitors	Lisinopril, ramipril, enalapril, perindopril	Inhibit ACE → ↓ angiotensin II, ↑ bradykinin → vasodilation + natriuresis	CKD/proteinuria, heart failure, post-MI, diabetic nephropathy	Cough (5–20%), hyperkalaemia, AKI, teratogenic (avoid in pregnancy)
ARBs	Losartan, valsartan, irbesartan, olmesartan, telmisartan	Block AT₁ receptor → vasodilation without bradykinin accumulation	ACE inhibitor-intolerant patients, CKD, heart failure; no cough	Hyperkalaemia, AKI; teratogenic; avoid dual RAAS blockade
Thiazide/thiazide-like diuretics	Chlorthalidone (preferred), HCTZ, indapamide	Block NCC in distal tubule → ↑ Na/water excretion → ↓ plasma volume	Chlorthalidone superior to HCTZ in outcome trials (ALLHAT); affordable	Hypokalaemia, hyponatraemia, hyperuricaemia; ineffective at eGFR <30
Dihydropyridine CCBs	Amlodipine, nifedipine XL, lercanidipine, felodipine	Block L-type Ca²⁺ channels in vascular smooth muscle → vasodilation	Effective in black patients (where RAAS blockers are less effective), elderly	Peripheral oedema, flushing, reflex tachycardia; CYP3A4 substrate (amlodipine)
Non-DHP CCBs	Diltiazem, verapamil	Block L-type Ca²⁺ in cardiac and vascular tissue → rate control + vasodilation	Rate control in AF + hypertension, angina	CYP3A4 inhibitors — many DDIs; avoid with beta-blockers (AV block); HF with reduced EF
Beta-blockers	Metoprolol succinate, bisoprolol, atenolol, carvedilol	Block β₁ adrenoceptors → ↓ heart rate, cardiac output, renin release	Post-MI, heart failure with reduced EF, AF rate control, angina	Not first-line for uncomplicated hypertension; mask hypoglycaemia; bronchospasm
MRAs (mineralocorticoid receptor antagonists)	Spironolactone, eplerenone	Block aldosterone receptor → natriuresis + K⁺ retention	Resistant hypertension (4th-line), heart failure with reduced EF, primary aldosteronism	Hyperkalaemia risk especially with ACE inhibitors/ARBs or CKD; gynaecomastia (spironolactone)
Loop diuretics	Furosemide, bumetanide, torasemide	Inhibit NKCC2 in thick ascending limb → potent natriuresis	Preferred diuretic at eGFR <30, acute decompensated heart failure, pulmonary oedema	Hypokalaemia, hyponatraemia, ototoxicity (high-dose IV); short duration requires BD dosing

Is lisinopril a beta blocker or calcium channel blocker?

A common question is whether lisinopril is a beta blocker or a calcium channel blocker. Lisinopril is neither — it is an ACE inhibitor (angiotensin-converting enzyme inhibitor). ACE inhibitors work by blocking the enzyme that converts angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Beta blockers (e.g. metoprolol, bisoprolol) block beta-adrenergic receptors to reduce heart rate and cardiac output, while calcium channel blockers (e.g. amlodipine, diltiazem) block L-type calcium channels in vascular smooth muscle and cardiac tissue. Although all three classes lower blood pressure, their mechanisms, side-effect profiles, and indications differ substantially. See the DailyMed lisinopril label ↗ and NCBI StatPearls — ACE inhibitors ↗ for detailed pharmacology.

Hyponatremia caused by antihypertensive drugs

Hyponatremia caused by drugs is an important clinical consideration in patients taking blood pressure medications. Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) are the most common drug cause of hyponatremia — they impair the kidney's diluting ability by blocking sodium reabsorption in the distal tubule while allowing continued free water reabsorption via ADH. Risk factors include older age, low body weight, low dietary sodium, and concurrent use of SSRIs or carbamazepine. Other drugs that can cause hyponatremia include loop diuretics (less commonly than thiazides), ACE inhibitors (rare, via SIADH-like mechanism), and desmopressin. Management involves identifying and discontinuing the offending agent, correcting sodium slowly (risk of osmotic demyelination if corrected too rapidly), and monitoring electrolytes. See the UpToDate — causes of hyponatremia ↗ and NCBI StatPearls — drug-induced hyponatremia ↗ for clinical guidance.

ACE inhibitors and ARBs — RAAS blockade

The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that regulates blood pressure and fluid balance. Renin (released by the kidney in response to low perfusion pressure) converts angiotensinogen to angiotensin I; ACE converts angiotensin I to angiotensin II — a potent vasoconstrictor that also stimulates aldosterone release (promoting sodium and water retention). ACE inhibitors interrupt this cascade at the ACE step; ARBs block the angiotensin II type-1 (AT₁) receptor downstream.

Beyond blood pressure, RAAS blockade reduces proteinuria in diabetic nephropathy and slows CKD progression, reduces cardiac remodelling after myocardial infarction, and improves survival in heart failure with reduced ejection fraction — making ACE inhibitors and ARBs the most versatile antihypertensive class. See the NCBI StatPearls review of ACE inhibitors ↗ for detailed pharmacology.

Teratogenicity: ACE inhibitors and ARBs are absolutely contraindicated in pregnancy (all trimesters) — they cause fetal renal tubular dysplasia, oligohydramnios, and neonatal renal failure. Switch to methyldopa, labetalol, or nifedipine in pregnancy. See pregnancy and drugs guide ↗.

Diuretics — choosing the right agent by renal function

Diuretics are among the most commonly prescribed antihypertensives. The three major classes differ in their site of action in the nephron and their efficacy at different levels of renal function:

Thiazide/thiazide-like (chlorthalidone, HCTZ, indapamide): Act on the distal convoluted tubule (NCC). Effective at eGFR ≥30. Chlorthalidone has a longer half-life (~50 h) than HCTZ (~8 h) and showed superior cardiovascular outcomes in the ALLHAT trial ↗.
Loop diuretics (furosemide, bumetanide, torasemide): Act on the thick ascending limb (NKCC2). Remain effective at eGFR <30. Use the creatinine clearance calculator to guide switching between thiazide and loop diuretics.
Potassium-sparing/MRAs (spironolactone, eplerenone): Reserve for resistant hypertension (4th agent); highest hyperkalaemia risk when combined with ACE inhibitors or ARBs, especially in CKD.

Frequently asked questions

What are the first-line drug classes for hypertension?

AHA/ACC 2017 hypertension guidelines ↗ and NICE NG136 (2023) ↗ recommend four first-line classes: thiazide/thiazide-like diuretics (chlorthalidone preferred over HCTZ); ACE inhibitors (lisinopril, ramipril); ARBs (losartan, valsartan); and dihydropyridine CCBs (amlodipine). All have equivalent BP lowering; choice is driven by comorbidities — e.g., ACE inhibitors for CKD/diabetic nephropathy, beta-blockers for post-MI or heart failure.

Why are ACE inhibitors and ARBs not used together?

Dual renin-angiotensin-aldosterone system (RAAS) blockade is contraindicated: the ONTARGET trial ↗ showed telmisartan + ramipril increased renal adverse events (hyperkalaemia, AKI, dialysis) without reducing cardiovascular death vs monotherapy. NICE NG136 ↗, ESC 2023 ↗, and AHA/ACC guidelines explicitly prohibit this combination. The same applies to ACE inhibitor + direct renin inhibitor (aliskiren) — also contraindicated per FDA safety communication. Use creatinine clearance and serum potassium to monitor renal function when using either drug class.

What is the mechanism of ACE inhibitor-related cough?

ACE inhibitors block angiotensin-converting enzyme (ACE/kininase II), which degrades bradykinin. Bradykinin accumulation in pulmonary tissue stimulates C-fibres, causing a dry persistent cough in 5–20% of patients (up to 40% in East Asian patients due to genetic differences in bradykinin metabolism). ARBs block the angiotensin II type-1 receptor directly and do not affect bradykinin — so they are the standard switch when cough occurs. See NCBI StatPearls — ACE inhibitors ↗ and the pharmacogenomics guide for genetic variation in ACE inhibitor response (e.g. bradykinin receptor polymorphisms).

What are the key drug interactions with antihypertensives?

Critical interactions: NSAIDs (ibuprofen, naproxen) blunt the antihypertensive effect of ACE inhibitors, ARBs, and diuretics — and increase AKI risk via combined reduction in renal perfusion (see renal dosing guide). Potassium-sparing diuretics + ACE inhibitors/ARBs → hyperkalaemia risk, especially in CKD. Diltiazem/verapamil (non-DHP CCBs) are strong CYP3A4 inhibitors — simvastatin co-prescription increases myopathy risk (FDA limits simvastatin ≤10 mg with verapamil). Beta-blockers + non-DHP CCBs → additive bradycardia/AV block, especially dangerous in patients with conduction disease. Check the FDA DDI table ↗ for full interaction data.

Is lisinopril a beta blocker or calcium channel blocker?

Lisinopril is an ACE inhibitor, not a beta blocker and not a calcium channel blocker. ACE inhibitors block the conversion of angiotensin I to angiotensin II — reducing vasoconstriction and aldosterone secretion. Beta blockers (metoprolol, bisoprolol) block β₁ adrenoceptors to reduce heart rate and cardiac output. Calcium channel blockers (amlodipine, diltiazem) block L-type Ca²⁺ channels. All lower blood pressure but have different mechanisms, side effects, and indications. See the DailyMed lisinopril label ↗ and NCBI ACE inhibitors ↗.

Which drugs can cause hyponatremia?

Thiazide diuretics (HCTZ, chlorthalidone, indapamide) are the most common drug cause of hyponatremia — they impair the kidney's diluting ability. Other causes: SSRIs (via SIADH), carbamazepine (SIADH), desmopressin, and rarely ACE inhibitors or loop diuretics. Risk factors: older age, low body weight, low Na intake. Management: identify and stop the offending drug; correct Na slowly (<8–10 mmol/L per 24 h) to avoid osmotic demyelination. See NCBI StatPearls — drug-induced hyponatremia ↗ and UpToDate — causes of hyponatremia ↗.

How should antihypertensives be adjusted in chronic kidney disease (CKD)?

ACE inhibitors/ARBs are first-line in CKD with proteinuria — they reduce intraglomerular pressure and slow CKD progression. Accept up to 30% creatinine rise and K⁺ <5.5 mmol/L after starting. Thiazides lose efficacy at eGFR <30 — switch to loop diuretics (furosemide, bumetanide, torasemide). Spironolactone and eplerenone carry high hyperkalaemia risk at eGFR <30 or baseline K⁺ >5.0 mmol/L — avoid or use only with very close monitoring. Use the creatinine clearance tool to estimate renal function. See KDIGO 2021 Blood Pressure in CKD guideline ↗ for full management recommendations.